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ABSTRACT:
Hepatocellular carcinoma (HCC) is one of the common malignances in the world 
and has high mortality in part due to development of acquired drug resistance. 
Therefore, it is urgent to investigate the molecular mechanism of drug resistance in 
HCC. To explore the underlying mechanism of drug resistance in HCC, we developed 
gemcitabine-resistant (GR) HCC cells. We used multiple methods to achieve our goal 
including RT-PCR, Western blotting analysis, transfection, Wound-healing assay, 
migration and invasion assay. We observed that gemcitabine-resistant cells acquired 
epithelial-mesenchymal transition (EMT) phenotype. Moreover, we found that PDGF-D 
is highly expressed in GR cells. Furthermore, down-regulation of PDGF-D in GR cells 
led to partial reversal of the EMT phenotype. Our findings demonstrated that targeting 
PDGF-D could be a novel strategy to overcome gemcitabine resistance in HCC.  
INTRODUCTION
Hepatocellular carcinoma (HCC) is a highly 
aggressive malignant disease, which predicted 26,190 
newly diagnosed cases and 19,590 deaths in the United 
States in 2012 [1]. Approximately 70% of the patients 
diagnosed with HCC cannot have curative surgery due 
to metastasis at the time of diagnosis, resulting in the 
median overall survival of only few months [1]. The high 
mortality is also partly due to acquired drug resistance 
during chemotherapy treatment [2]. It is well known that 
chemotherapy is a critical management for advanced 
HCC [3]. Thus, it is pivotal to explore the underlying 
mechanism of drug resistance and subsequently find ways 
to overcome such drug resistance for achieving better 
treatment outcome in HCC patients. 
Gemcitabine  (2’,2’-difluorodeoxycytidine),  a 
deoxycytidine analogue, is used as a chemotherapeutic 
drug or its combination with other agents for the treatment 
of advanced HCC [4]. For example, gemcitabine and 
oxaliplatin (GEMOX) have been considered as second-line 
treatment in patients with HCC pre-treated with sorafenib 
[5]. Moreover, chemotherapy with GEMOX prolonged 
a compete response in advanced fibrolamellar HCC [5]. 
Recent studies have identified that GEMOX are effective Oncotarget 2013; 4: 2000 www.impactjournals.com/oncotarget
with manageable toxicity in patients with advanced 
HCC [6]. Additionally, gemcitabine in combination with 
cisplatin prolonged the survival in advanced HCC [7]. 
Although gemcitabine is a promising drug to be considered 
for the treatment of HCC, tumor cells acquire resistance 
to gemcitabine that causes treatment failure for improving 
the survival of HCC patients. Thus, it is necessary to 
understand the underlying mechanism of drug resistance 
to gemcitabine and find a novel therapeutic strategy for 
effective treatment of patients with advanced HCC.  
Mounting evidence demonstrates that chemo-
resistance is associated with the acquisition of epithelial-
mesenchymal transition (EMT)-like phenotypic change 
of cancer cells [8]. EMT is a process by which epithelial 
cells switch to mesenchymal phenotypic cells, resulting 
in increased motility and invasion [9]. During EMT, 
cells lose epithelial cell-cell junction and epithelial 
markers such as E-cadherin, as well as gain mesenchymal 
properties with high expression of mesenchyaml 
molecular markers including Vimentin, Snail, Slug, zinc-
finger E-box binding homeobox 1 (ZEB1) and ZEB2 [10]. 
Multiple studies have revealed that chemo-resistance cells 
often acquired EMT phenotype [8]. Our previous studies 
have shown that gemcitabine-resistant (GR) pancreatic 
cancer cells showed phenotypic changes consistent 
with EMT and up-regulated Notch pathway [11]. In the 
current study, we found that GR HCC cells acquired EMT 
characteristics.  Moreover,  we  identified  that  Platelet-
Figure 1: HCC gemcitabine-resistant (GR) cells acquired EMT phenotype. A, MTT assay was performed in parental HepG2, 
SMMC-7721, HepG2 GR, and SMMC-7721 GR cells, respectively. B, Cell morphology was observed by microscopy. Parental HepG2 and 
SMMC-7721 cells displayed an epithelioid and cobblestone appearance with little pseudopodia. In contrast, HepG2 GR and SMMC-7721 
GR cells showed loss of cell polarity and increased formation of pseudopodia, leading to elongated, irregular fibroblastoid morphology. C, 
Invasion assay was conducted to measure the invasive capacity in HepG2 and HepG2 GR cells. * P<0.05 vs control. D, Invasion assay was 
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derived growth factor-D (PDGF-D) signaling pathway 
is involved in the acquisition of EMT phenotype of GR 
HCC cells. Furthermore, inhibition of PDGF-D pathway 
partly reversed EMT to mesenchymal-epithelial transition 
(MET). Our findings suggest that PDGF-D pathway is 
involved in chemo-resistance and EMT characteristics of 
HCC cells, demonstrating that targeting PDGF-D could 
overcome resistance of HCC to gemcitabine. Therefore, 
inhibition of PDGF-D may have therapeutic implications 
for the successful treatment of HCC patients.  
RESULTS
Establishment of gemcitabine-resistant HCC cell 
lines. 
To develop HCC cell lines chronically resistant to 
gemcitabine, HepG2 and SMMC-7721 cells were exposed 
to increasing concentrations of gemcitabine. Specifically, 
to establish gemcitabine resistant HCC cell line, cells 
were continuously exposed to gemcitabine for more than 
12 months. After surviving cells reached more than 70% 
confluency,  they  were  passaged  by  trypsinization  and 
exposed to increased concentration of gemcitabine. The 
process was repeated until resultant HCC cells displayed 
resistance to the growth inhibitory properties of 10 µg/
ml gemcitabine. The resulting cells were designated 
as HCC GR cells. HCC GR cells were cultured for 
additional 3 months in DMEM medium containing 10 µg/
ml gemcitabine for this study. 
Morphologic changes in HCC GR cells.
Our previous study has shown that GR pancreatic 
cancer cells had morphologic changes consistent with 
EMT [11]. Therefore, we tested whether HCC GR cells 
have markedly morphologic changes compared with the 
parental cell lines. As illustrated in Figure 1B, HepG2 
and SMMC-7721 cells displayed a rounded shape and 
little formation of pseudopodia. In contrast, HepG2 GR 
and SMMC-7721 GR cells had phenotypic changes 
including loss of cell polarity and increased formation of 
pseudopodia, leading to elongated, irregular fibroblastoid 
Figure 2: HCC GR cells have increased migratory capacity. A, Wound assays were performed to compare the migratory potential 
of HepG2 and HepG2 GR cells. B, Wound assays were conducted to detect the migratory capacity of SMMC-7721 and SMMC-7721 GR 
cells. C, Cell attachment and detachment assays were conducted in HepG2 and HepG2 GR cells. * P<0.05 vs control. D, Cell attachment 
and detachment assays were performed in SMMC-7721 and SMMC-7721 GR cells. * P<0.05 vs control.
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morphology  (Figure  1B). These  morphologic  changes 
suggest that HCC GR cells acquired a mesenchymal 
phenotype.
Increased invasion activity in HCC GR cells.
 It has been known that after EMT, cells enhance 
migratory  and  invasive  activity.  To  confirm  the 
EMT progress in HCC GR cells, we conducted the 
invasion assay. We found that HepG2 GR cells showed 
approximately 4-fold increase in the number of cells 
migrating through a Matrigel-coated membrane compared 
with HepG2 cells (Figure 1C). Consistently, SMMC-7721 
GR cells have significantly increased invasion activity 
(Figure 1D).  
HCC GR cells have increased motility activity. 
To further confirm whether HCC GR cells acquired 
EMT characteristics, we compared the migratory potential 
of HCC GR cells and parental HCC cells using a scratch 
wound-healing assay. As demonstrated in Figure 2A, 2B, 
Figure 3: HCC GR cells have high expression of EMT markers. A, RT-PCR assay was performed to detect the mRNA levels 
of E-cadherin, Slug, Snail, and Vimentin in HepG2 GR and SMMC-7721 GR cells. * P<0.05 vs control. B, Left panel, Western blotting 
analysis was conducted to measure the expression of E-cadherin, Snail, Slug, and Vimentin in SMMC-7721 and SMMC-7721 GR cells. 
Right panel, Quantitative results are illustrated for left panel. SMMC: SMMC-7721. * P<0.05 vs control. C, Left panel, Western blotting 
analysis was used to detect the expression of E-cadherin, Snail, Slug, and Vimentin in HepG2 and HepG2 GR cells. Right panel, Quantitative 
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HepG2 GR and SMMC-7721 GR cells have significantly 
increased numbers of cells migrating across the wound, 
suggesting that HCC GR cells acquired enhanced 
migration capacity. 
HCC GR cells have enhanced detached and 
attachment activity. 
It has been well accepted that cell detachment from 
the matrix is a crucial component in cancer spreading, 
often leading to tumor recurrence. Cancer cell attachment 
to the secondary site is the hallmark of tumor metastatic 
process. Consistent with this notion, we found that HepG2 
GR and SMMC-7721 GR cells have increased capacity of 
attachment and detachment (Figure 2C, 2D). 
HCC GR cells have EMT marker changes. 
To further identify whether HCC GR cells have 
the specific molecular changes consistent with EMT, we 
measured the expression of markers of epithelial and 
mesenchymal  phenotypes  using  RT-PCR  and  Western 
blotting analysis, respectively. We observed that the 
expression of epithelial adhesion molecule E-cadherin 
was significantly reduced in HepG2 GR and SMMC-7721 
GR cells (Figure 3). On the contrary, the expression of 
mesenchymal markers including Vimentin, Snail and Slug 
was elevated in HepG2 GR and SMMC-7721 GR cells 
Figure 4: HCC GR cells have high expression of PDGF-D. A, RT-PCR assay was done to quantify the mRNA level of PDGF-D 
in HepG2 GR and SMMC-7721 GR cells. SMMC: SMMC-7721. * P<0.05 vs control. B, Western blotting analysis was performed to detect 
the expression of PDGF-D and PDGFRβ in HepG2 and HepG2 GR cells. SMMC: SMMC-7721. C, Quantitative results are illustrated for 
panel B. * P<0.05 vs control. D, Left paenl, Western blotting analysis was conducted to detect the inhibitory efficacy of PDGF-D siRNA in 























SMMC SMMC GROncotarget 2013; 4: 2004 www.impactjournals.com/oncotarget
(Figure 3), indicating that the expression of these factors 
plays a critical role in gemcitabine-induced EMT of HCC 
cell.  
Activation of PDGF-D pathway in HCC GR cells. 
Since PDGF-D has been reported to play a pivotal 
role in the EMT induction during tumor progression 
[12], we measured the expression of PDGF-D at mRNA 
and  protein  levels  by  RT-PCR  and  western  blotting, 
respectively. We observed an increased activation of 
PDGF-D at both mRNA and protein levels in HepG2 GR 
and SMMC-7721 GR cells (Figure 4A, 4B). Moreover, 
we found that the expression of PDGFRβ was increased 
in HepG2 GR and SMMC-7721 GR cells compared with 
their parental cells (Figure 4B). Consistently, we also 
found the activation of PDGF-D pathway in BxPC-3 GR 
and PANC-1 GR pancreatic cancer cells (data not shown), 
suggesting that PDGF-D may be involved in gemcitabine-
Figure 5: PDGF-D contributes to the regulation of EMT markers in HCC GR cells. A, Down-regulation of PDGF-D 
caused reversal of EMT phenotype of HCC GR cells. HepG2 GR and SMMC-7721 GR cells transfected with control siRNA exhibited a 
fibroblastic-type phenotype, while these GR cells transfected with PDGF-D siRNA display round-like epithelial cell shape.  B, HCC GR 
cells transfected with control siRNA or PDGF-D siRNA were used for assessing the expression of markers of epithelial and mesenchymal 
phenotypes using Real-time RT-PCR.  SMMC: SMMC-7721. CS: control siRNA; PS: PDGF-D siRNA. * P<0.05 vs control. C, Real-time 
RT-PCR was used to quantify PDGF-D and PDGFRβ mRNA expression in HepG2 GR cells transfected with PDGF-D siRNA. CS: control 
siRNA; PS: PDGF-D siRNA.  *, P<0.05 compared with control siRNA.  D, HCC GR cells transfected with control siRNA or PDGF-D 
siRNA were used for assessing the expression of markers of epithelial and mesenchymal phenotypes by Western blotting analysis. CS: 
control siRNA; PS: PDGF-D siRNA.
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induced EMT in human cancer cells.   
Down-regulation of PDGF-D reverses EMT to 
MET in GR cells. 
To further confirm the role of PDGF-D in HCC 
GR cells containing EMT features, we explored whether 
inhibition of PDGF-D by its specific siRNA could reverse 
EMT to MET. We found that PDGF-D siRNAs remarkably 
inhibited the expression of PDGF-D in HepG2 GR cells 
(Figure 4D) and SMC-7721 GR cells (data not shown). 
Subsequently, we assessed whether EMT phenotype was 
reversed  in  HCC  GR  cells  transfected  with  PDGF-D 
siRNA. We observed that HepG2 GR and SMMC-7721 
GR  cells  transfected  with  PDGF-D  siRNA  displayed 
round cell-like morphology (Figure 5A). Moreover, we 
found that the expression of E-cadherin was significantly 
increased, while the expression of mesenchymal markers 
was decreased in HCC GR cells transfected with PDGF-D 
siRNA (Figure 5B, 5D), suggesting that down-regulation 
of PDGF-D led to the reversal of EMT to MET phenotype. 
Down-regulation of PDGF-D signaling enhances 
detachment and inhibits the migration and 
invasion of HCC GR cells. 
To further validate the reversal of EMT by PDGF-D 
siRNA, we measured the cell detachment, attachment, 
and motility capacities. As expected, we observed that 
down-regulation of PDGF-D by siRNA markedly reduced 
the migratory (Figure 6A) and invasive ability of HCC 
GR  cells  (Figure  6B).  Consistent  with  these  results, 
PDGF-D siRNA inhibited cell motility as assessed by 
wound healing assay in SMMC-7721 GR cells (Figure 
6C). Moreover, HCC GR cells transfected with PDGF-D 
siRNA displayed decreased detachment and attachment 
Figure 6: Down-regulation of PDGF-D inhibited cell migration and invasion, and reduce detachment of HepG2 GR 
cells. A, Transfection of HepG2 GR cells and SMMC-7721 GR cells with PDGF-D siRNA inhibited cell migration. B, PDGF-D siRNA 
suppressed cell invasion of HepG2 GR and SMMC-7721 GR cells by Transwell invasion assay. C, SMMC-7721 GR cells transfected 
with PDGF-D siRNA caused decreased motility capacity as assessed by Wound healing assay. D, HepG2 GR and SMMC-7721 GR cells 
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capacity (Figure 6D). These results clearly suggest that 
down-regulation  of  PDGF-D  inhibited  PDGFRβ  and 
consequently up-regulated E-cadherin as well as down-
regulated mesenchymal protein expressions, resulting in 
the reversal of the EMT to a MET phenotype with less cell 
migration and invasion characteristics.  
DISCUSSION
HCC is the one of leading causes of cancer-related 
deaths in the United States [1]. Surgically unresectable 
patients have a poor prognosis due to distant metastases 
and in part due to intrinsic and acquired resistance to 
chemotherapeutic drugs. A line of evidence has revealed 
that drug resistance can be divided into oncogenic and 
nononcogenic [13, 14]. Nononcogenic mechanisms 
include expression of energy-dependent drug transporters 
that eject anti-cancer drugs from cells, induction of 
drug detoxification, and mutation in drug-targets [15]. 
Oncogenic drug resistance is due to activation of cellular 
pathways involved in cell proliferation and survival, 
leading to uncontrolled malignant growth [13]. In 
line with this concept, multiple key cellular signaling 
pathways, including Akt, mTOR (mammalian target of 
rapamycin), NF-κB (nuclear factor-kappa B) and Notch, 
have been demonstrated to be involved in drug resistance 
to conventional chemotherapeutics [16-20]. Although the 
causes of drug resistance have been explored for many 
years, the mechanisms responsible for drug resistance are 
still largely elusive [21, 22]. Therefore, elucidation of the 
underlying mechanism of drug resistance is important 
to develop novel strategies for effective treatment of 
advanced HCC patients. 
Recently, accumulating evidence has demonstrated 
that drug-resistant cancer cells are associated with the 
EMT process in human cancers including HCC. For 
example, Tamoxifen-resistant MCF7 breast cancer cells 
showed  EMT  characteristics  with  altered  β-catenin 
phosphorylation [23]. Similarly, oxaliplatin-resistant 
colorectal cancer cells underwent EMT progression 
[24]. Paclitaxel-resistant ovarian cancer cells displayed 
decreased E-cadherin expression, and increased expression 
of mesenchymal markers consistent with EMT phenotype 
[25]. Moreover, gefitinib-resistant lung cancer cells have 
EMT phenotype with down-regulation of E-cadherin and 
up-regulation of Vimentin [26]. In line with these reports, 
we have previously observed that gemcitabine-resistant 
pancreatic cancer cells acquired EMT features [11]. 
Consistent with these findings, in the current study, we 
found that HepG2 GR cells and SMMC-7721 GR cells 
demonstrated altered morphological characteristics of cells 
similar to EMT with decreased E-cadherin and increased 
Vimentin, Snail and Slug, suggesting that there is a link 
between chemo-resistance and EMT in HCC. 
PDGF-D signaling pathway has been reported to be 
involved in the regulation of various cellular processes, 
Figure 7: A proposed model for PDGF-D signaling 
pathway in HCC GR EMT-type cells. HCC GR cells 
acquired  EMT  phenotype  where  PDGF-D  was  up-regulated, 









Table 1: The primers used for RT-PCR analysis.









Table 2: The RNA sequences for specific siRNAs.
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such as cell proliferation, apoptosis, invasion, metastases 
and EMT in human cancer [27]. It is known that PDGF-D 
exerts its biological function through specifically binding 
to and activating its cognate receptor PDGFR-β, leading 
to phosphorylation of PDGFR-β and subsequent activation 
of its target genes such as PI3K/Akt, mTOR, Notch, NF-
κB, CXCR4 (C-X-C chemokine receptor type 4), and 
Bcl-2 [28, 29]. Our previous studies have shown that 
PDGF-D could facilitate EMT in prostate cancer cells 
[30, 31]. Specifically, over-expression of PDGF-D caused 
EMT phenotype in PC3 prostate cancer cells with loss 
or relocation of E-cadherin and increased expression 
of  Vimentin  and  Nestin,  suggesting  that  PDGF-D 
overexpression contributes to EMT in human cancers 
[31]. Moreover, miR-200 regulated PDGF-D-mediated 
EMT partly through down-regulation of ZEB1, ZEB2 and 
Snail, and up-regulation of E-cadherin in prostate cancer 
cells [32]. In agreement with the role of PDGF-D in EMT, 
we observed high expression of PDGF-D in HCC GR 
cells consistent with EMT phenotype. More importantly, 
down-regulation of PDGF-D in HepG2 GR and SMMC-
7721 GR cells reversed EMT to MET, demonstrating that 
PDGF-D plays an important role in GR-induced EMT in 
HCC. 
A number of studies have demonstrated that cells 
that acquired drug resistant via nononcogenic do not 
become increasing malignant [15]. However, resistance 
to a drug through activation of oncogenic pathways is 
associated with highly aggressive cancer phenotype 
including enhanced invasiveness, metastasis, and poor 
overall survival [13]. In support of this note, we found that 
PDGF-D was highly expressed in HCC GR cells, which 
is consistent with its function in the acquisition of EMT 
phenotype and enhanced migration and invasion (Figure 
7). More importantly, inhibition of PDGF-D led to the 
reversal of EMT to MET, resulting in decreased invasive 
behavior of HCC GR cells. These results suggest that the 
inactivation of PDGF-D could be a promising approach for 
overcoming chemoresistance toward effective treatment 
outcome of advanced HCC patients.  
MATERIALS AND METHODS
Cell culture, reagents and antibodies:
HepG2 and SMMC-7721 cells were cultured 
at 37°C in 5% CO2  in  Dulbecco’s  modified  Eagle’s 
medium  (DMEM;  Gibco,  Gaithersburg,  MD,  USA) 
supplemented with 10% fetal bovine serum. MTT 
[3-(4,5-dimethythiazol- 2-yl)-2,5-diphenyl tetrazolium 
bromide] was purchased from Sigma (St. Louis, Mo). 
Primary  antibodies  against  E-cadherin,  Snail,  Slug, 
Vimentin, GAPDH, PDGF-D, and PDGFRβ were bought 
from Santa Cruz Biotechnology (Santa Cruz, CA). The 
secondary antibodies were also obtained from Santa Cruz 
Biotechnology.  
Cell proliferation studies by MTT assay: 
The HCC cells and HCC gemcitabine-resistant 
(GR) cells (5 ×103) were seeded at equal densities into a 
96-well culture plate for overnight incubation. Then, the 
medium was replaced with medium containing different 
concentrations of gemcitabine for 72 hours. MTT assay 
was conducted as described before [33].   
Wound healing assay: 
The HCC cells and HCC GR cells were seeded in 
6-well plate until the cells grew to 90–95% confluency. 
The scratch wound was generated in the surface of the 
plates using a pipette tip. Photographic images were taken 
from HCC and HCC GR cells at 0 hour and 16 hours.   
Cell attachment and detachment assay: 
Cell attachment and detachment assays were 
conducted as described before [31]. Briefly, for attachment 
assay, HCC cells, HCC GR cells , and GR cells transfected 
with PDGF-D siRNA were seeded in 24-well plates at 5 
X 104 cells per well. Unattached cells were removed 
after 1 hour incubation, and the attached cells were 
counted after trypsinization. The data were presented as 
a percentage of the attached cells compared to total cells. 
For cell detachment assay, after 24 hours incubation, the 
cells were incubated with 0.05% trypsin for 3 minutes 
to detach the cells. Then, the culture medium was added 
to inactivate the trypsin and the detached cells were 
collected. The remaining cells were incubated with 0.25% 
trypsin to detach and counted. The data were presented as 
a percentage of the detached cells to total cells.    
Transwell migration and invasion assays: 
The migration of HCC cells was conducted using 
a 24-well Transwell chamber (Corning) with gelatin-
coated  polycarbonate  membrane  filter.  The  invasive 
capacity of HCC cells was performed using Transwell 
inserts with Matrigel (BD Biosciences). After incubation 
for 16 h, the upper surfaces of the Transwell chambers 
were scraped with cotton swabs, and the migrated and 
invaded cells were fixed with 4% paraformaldehyde, and 
then stained with Giemsa solution. The stained cells were 
photographed and counted under a light microscope in five 
randomly-selected fields. Oncotarget 2013; 4: 2008 www.impactjournals.com/oncotarget
RNA extraction and reverse transcription-PCR 
analysis for gene expression: 
The total RNA from HCC cells and HCC GR cells 
was isolated with Trizol (Invitrogen) and purified with 
RNeasy Mini Kit and RNase-free DNase Set (Qiagen) 
according to the manufacturer’s protocols. The primers 
used  in  the  PCR  reactions  are  listed  in  Table  I.  The 
expression of GAPDH was used as internal control. RT-
PCR amplifications were performed as described before 
[11, 34].
Protein extraction and Western blotting: 
Cells were harvested and lysed with RIPA buffer 
(1 × PBS, 1% Nonidet P40, 0.5% sodium deoxycholate, 
0.1% SDS, and protease inhibitor cocktail). The protein 
concentrations were measured using the Bio-Rad protein 
assay kit (Bio-Rad Laboratories, CA). Immunoblotting 
was conducted with standard protocols as described 
previously [35]. 
Transfection: 
Cells were seeded in six-well plates and transfected 
with PDGF-D siRNA, control siRNA using Lipofectamine 
2000 as described earlier [36]. The sequences for PDGF-D 
siRNA and control siRNA are listed in Table II. After the 
indicated periods of incubation, the cells were subjected 
to further analysis as presented under the results section.
Statistical Analysis: 
Values were shown as means± SEM and analyzed 
using  GraphPad  Prism  4.0  (Graph  pad  Software,  La 
Jolla, CA). Statistical comparisons between different 
groups were performed using Student t test. P<0.05 was 
considered statistically significant.
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